EATG » Hepatitis

Hepatitis

HCV treatment found safe and effective in individuals with kidney disease

Highlights In patients with chronic kidney disease and Hepatitis C virus infection, sofosbuvir-based direct-acting antiviral therapy was safe and effective. Patients with stage 3 kidney disease who were cured of…

Injection drug users with HCV in Scotland lack awareness of DAA efficacy

Most people who inject drugs were not aware of currently available, highly effective hepatitis C treatments, according results of a national survey in Scotland presented at the International Symposium on…

Among injection drug users in San Francisco, young adults at highest risk for HCV

Adult injection drug users aged 30 years or younger are both at the highest risk for acquiring hepatitis C and transmitting HCV, according to a presentation at the International Symposium…

People who use drugs require prioritization, not exclusion, in HCV elimination

An international conference bringing together hepatitis C experts from around the world is today calling for strategies to prioritise people who use drugs, saying hepatitis C elimination is impossible without…

Unitaid publishes Technology and Market Landscape for Hepatitis C Medicines

Geneva, 06 September 2017 – The World Health Organization (WHO) estimates that 71 million people worldwide are chronically infected with Hepatitis C virus (HCV). Of those, 2.3 million people are co-infected…

Cirrhosis is linked with hepatitis C treatment failure among those who also have HIV

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C. Among people coinfected with HIV and hepatitis C virus…

Hepatitis B: Search for the cure and challenges that remain

The World Health Organization (WHO) estimates that approximately 257 million people worldwide are living with hepatitis B virus (HBV) infection.1 In 2015, hepatitis B claimed 887,000 lives, mostly due to…

VBI Vaccines to advance Phase 3 study for Sci-B-Vac

VBI Vaccines announces FDA acceptance of Investigational New Drug Application for Sci-B-Vac® Phase 3 clinical program -- Sci-B-Vac® is a third-generation hepatitis B vaccine, approved for use in Israel and…

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated anti-HBc

Results of a prospective Italian study Abstract Background and aim Antibodies against hepatitis B core antigen (anti-HBc) are found in 14–44% of patients with HIV infection, but it is still…

Risk of HBV reactivation low in DMARD users

More common with chronic versus resolved infection Hepatitis B virus (HBV) reactivation was unlikely in patients receiving disease-modifying antirheumatic drugs (DMARDs) whose HBV infection had resolved, according to a meta-analysis.…